Plain-English translation of NCT04957511 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers want to understand whether the bacteria living in your gut affect how well immunotherapy works for gynecological cancer. This small pilot study will collect samples from 30 women before, during, and after immunotherapy treatment to analyze the composition of their gut bacteria and see if there's a connection to how patients respond to the medication.
Recent research suggests that gut bacteria may play an important role in how well immunotherapy works, but this hasn't been studied in gynecological cancer patients yet. This trial will gather early evidence to help design future studies that could eventually lead to ways of improving treatment outcomes for women like you.
You likely qualify if…
You likely don't qualify if…
You will provide stool, blood, saliva, and vaginal samples at three times: before you start immunotherapy, after you've received four doses of the medication, and when your treatment is complete. You'll also answer a brief food questionnaire at the start. Researchers will analyze these samples to look for patterns in your gut bacteria and whether they relate to how well your treatment works.
AI-generated summary from trial data · Aug 24, 2026 · Not medical advice
United States
Sponsor
Viome
Collaborators
AdventHealth
Enrollment target
~30 participants
Started
June 2021
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Momchilo Vuyisich, PhD
Viome Life Sciences
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.